%PDF-1.3
%ºß¬à
3 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 4 0 R
>>
endobj
4 0 obj
<<
/Length 3542
>>
stream
0.5670000000000001 w
0 G
0.09 0.64 0.29 rg
0. 841.8899999999999864 595.2755905511811534 -113.3858267716535551 re
f
BT
/F2 22 Tf
25.2999999999999972 TL
1. g
139.1277952755905858 771.0238582677164914 Td
(INNOVA TRIALS LLC REPORT) Tj
ET
BT
/F2 14 Tf
16.0999999999999979 TL
0. g
56.6929133858267775 671.8112598425196893 Td
(SITE DETAILS) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
56.6929133858267775 643.4648031496062686 Td
(Site Name: Santiago) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
56.6929133858267775 626.4569291338582389 Td
(Location: Montevideo, Uruguay) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
56.6929133858267775 609.4490551181102092 Td
(Status: TokenSent) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
56.6929133858267775 592.4411811023621794 Td
(Score: 0%) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
56.6929133858267775 575.4333070866141497 Td
(Registered: 9/2/2026) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
340.157480314960651 643.4648031496062686 Td
(Evaluated: Pending) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
340.157480314960651 626.4569291338582389 Td
(Evaluated By: N/A) Tj
ET
0.78 G
56.6929133858267775 544.2522047244093528 m
538.5826771653544256 544.2522047244093528 l
S
BT
/F2 14 Tf
16.0999999999999979 TL
0. g
56.6929133858267775 501.7325196850393354 Td
(EVALUATION SUMMARY) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 459.2128346456692611 Td
(1. [Infrastructure] Does the site have access to local laboratories?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 439.3703149606298552 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 411.0238582677164914 Td
(2. [Infrastructure] Do you have a functioning generator?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 391.1813385826770855 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 362.8348818897637216 Td
(3. [Infrastructure] Do you have strict control over medical equipment calibrations \(thermometers,) Tj
T* (scales, blood pressure monitors, others\)?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 328.8191338582676053 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 300.4726771653542983 Td
(4. [Infrastructure] Do you have documented management for the disposal of pathogenic waste \(waste) Tj
T* (from procedures, laboratory, among others\)?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 266.4569291338582389 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 238.1104724409448181 Td
(5. [Infrastructure] Does the site have a pharmacy dedicated exclusively to clinical research for the) Tj
T* (preparation and dispensing of the Investigational Product \(IP\)? Will the IP storage be carried out in) Tj
T* (the pharmacy?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 189.9214960629919915 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 161.5750393700786844 Td
(6. [Infrastructure] What equipment do you have for IP refrigeration? \(e.g., Freezer -20°C to -30°C,) Tj
T* (-70°C to -80°C, -135°C\)) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 127.559291338582625 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 99.2128346456692043 Td
(7. [Infrastructure] Describe what resources, equipment, and/or facilities the site has available for use) Tj
T* (in the study.) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 65.1970866141731449 Td
(Answer: Not Answered) Tj
ET
BT
/F1 8 Tf
9.1999999999999993 TL
0.588 g
230.4777952755905801 28.3464566929134207 Td
(Generated on 9/2/2026 - Innova Trials) Tj
ET
endstream
endobj
5 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 6 0 R
>>
endobj
6 0 obj
<<
/Length 3822
>>
stream
0.5670000000000001 w
0.78 G
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 756.8506299212598378 Td
(8. [Infrastructure] Does the site have the capacity to send digital images for centralized review? Does) Tj
T* (the site have sufficient high-speed internet connectivity to operate electronic data capture \(EDC\)) Tj
T* (systems?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 708.6616535433070112 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 680.3151968503937042 Td
(9. [Infrastructure] Does the site have 24-hour observation and/or overnight stay capacity available for) Tj
T* (clinical research?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 646.2994488188976447 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 617.952992125984224 Td
(10. [Infrastructure] Can the site offer afternoon, weekend, and/or holiday service hours for study) Tj
T* (visits, if required? Does the site have the capacity to administer medication during weekends for) Tj
T* (continuous dosing schedules?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 569.7640157480313974 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 541.4175590551180903 Td
(11. [Infrastructure] Does the site have an automated and documented temperature monitoring system) Tj
T* (for the storage of biological samples?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 507.4018110236219741 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 479.0553543307086102 Td
(12. [Infrastructure] How are source documents corresponding to clinical research archived and) Tj
T* (protected?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 445.0396062992125508 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 416.69314960629913 Td
(13. [Infrastructure] Do you have a documented circuit for temperature control of each thermometer at) Tj
T* (the site? What type of thermometers do you use for recording?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 382.6774015748030706 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 354.3309448818897067 Td
(14. [Infrastructure] Do you have a laboratory for sample processing? In the case of being a provider,) Tj
T* (do you have an evaluation system?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 320.3151968503935905 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 291.9687401574802834 Td
(15. [Infrastructure] Do you have a circuit designed for double-blind studies?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 272.1262204724408775 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 243.7797637795274568 Td
(16. [Staff] Does the site have enough properly trained staff to guarantee eCRF loading within 5) Tj
T* (business days after the patient's visit?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 209.7640157480313974 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 181.4175590551179766 Td
(17. [Staff] Do you have specific staff for the following roles: PI, SI, SC, research nursing, data) Tj
T* (manager, contract manager, recruiters, others?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 147.4018110236219172 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 119.0553543307086102 Td
(18. [Staff] Is there any member of your team designated as responsible for the processing and) Tj
T* (shipment of biological samples?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 85.0396062992125508 Td
(Answer: Not Answered) Tj
ET
BT
/F1 8 Tf
9.1999999999999993 TL
0.588 g
230.4777952755905801 28.3464566929134207 Td
(Generated on 9/2/2026 - Innova Trials) Tj
ET
endstream
endobj
7 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 8 0 R
>>
endobj
8 0 obj
<<
/Length 3836
>>
stream
0.5670000000000001 w
0.78 G
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 756.8506299212598378 Td
(19. [Staff] Do you have a system for updating staff documentation? \(CV, GCP, training\)?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 737.0081102362204319 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 708.6616535433070112 Td
(20. [Staff] Do you have documented traceable initial and continuous training processes in clinical) Tj
T* (research?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 674.6459055118109518 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 646.2994488188976447 Td
(21. [Staff] Is there a clearly defined person responsible for on-site and remote monitoring?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 626.4569291338582389 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 598.1104724409448181 Td
(22. [Quality Management] Are there written, current, versioned, and accessible SOPs for staff?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 578.2679527559055259 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 549.9214960629921052 Td
(23. [Quality Management] Does it have formal internal audit systems or a quality management) Tj
T* (system? Is there a documented and in-use CAPA system?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 515.9057480314959321 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 487.559291338582625 Td
(24. [Quality Management] Does the center have ISO or other certifications?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 467.716771653543276 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 439.3703149606298552 Td
(25. [Quality Management] Is there a formal record of errors in taking informed consent from the) Tj
T* (patient?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 405.3545669291337958 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 377.0081102362204319 Td
(26. [Quality Management] Does the center have ISO or other certifications?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 357.1655905511810261 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 328.8191338582676053 Td
(27. [Quality Management] Are screen failures and dropouts systematically recorded? And SF rate?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 308.9766141732283131 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 280.6301574803148924 Td
(28. [Quality Management] Do you have documentation of the major deviation rate of the center in the) Tj
T* (last year?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 246.614409448818833 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 218.2679527559054122 Td
(29. [Technology] Do you have an electronic medical record \(EMR\)?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 198.4254330708660063 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 170.0789763779526993 Td
(30. [Technology] In which technological systems do you have experience? \(e.g., eConsent, eCOA,) Tj
T* (eISF, Medidata Rave, Oracle RDC, Veeva Vault\)) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 136.0632283464566399 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 107.7167716535432191 Td
(31. [Data Management] Do you measure the average query resolution time \(Queries Average TAT\)?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 87.8742519685038133 Td
(Answer: Not Answered) Tj
ET
BT
/F1 8 Tf
9.1999999999999993 TL
0.588 g
230.4777952755905801 28.3464566929134207 Td
(Generated on 9/2/2026 - Innova Trials) Tj
ET
endstream
endobj
9 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 10 0 R
>>
endobj
10 0 obj
<<
/Length 3835
>>
stream
0.5670000000000001 w
0.78 G
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 756.8506299212598378 Td
(32. [Data Management] Is there a data transmission tracking/control system to the CRF?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 737.0081102362204319 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 708.6616535433070112 Td
(33. [Data Management] Is there documented follow-up of actions derived from monitoring \(Follow up) Tj
T* (letter\)?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 674.6459055118109518 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 646.2994488188976447 Td
(34. [Patient Safety] Is there an international safety system for medication-related SAEs?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 626.4569291338582389 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 598.1104724409448181 Td
(35. [Patient Safety] Does the site have a fully equipped and available emergency service \(ER\)?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 578.2679527559055259 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 549.9214960629921052 Td
(36. [Patient Safety] Do you have a system that ensures AEs and SAEs are reported in a timely) Tj
T* (manner?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 515.9057480314959321 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 487.559291338582625 Td
(37. [Scientific Reputation] Do you have a history of external audits/inspections without critical) Tj
T* (findings in any of them?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 453.5435433070865656 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 425.1970866141731449 Td
(38. [Scientific Reputation] In which therapeutic specialties do you have experience with clinical) Tj
T* (trials?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 391.1813385826770855 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 362.8348818897637216 Td
(39. [Scientific Reputation] Does the center have verifiable experience in Phase I studies?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 342.9923622047243725 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 314.6459055118109518 Td
(40. [Scientific Reputation] Does the center have verifiable experience in Phase II–IV studies?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 294.8033858267715459 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 266.4569291338582389 Td
(41. [IMP Management] Does the site have a complete and traceable circuit for IMP handling?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 246.614409448818833 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 218.2679527559054122 Td
(42. [Sponsor Relationship] Does the site allow remote monitoring visits?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 198.4254330708660063 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 170.0789763779526993 Td
(43. [Sponsor Relationship] Does the site allow on-site monitoring visits?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 150.2364566929132934 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 121.8899999999998727 Td
(44. [Sponsor Relationship] Does the site grant study monitors direct and controlled access to the) Tj
T* (electronic medical record \(EMR\) for source data verification?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 87.8742519685038133 Td
(Answer: Not Answered) Tj
ET
BT
/F1 8 Tf
9.1999999999999993 TL
0.588 g
230.4777952755905801 28.3464566929134207 Td
(Generated on 9/2/2026 - Innova Trials) Tj
ET
endstream
endobj
11 0 obj
<</Type /Page
/Parent 1 0 R
/Resources 2 0 R
/MediaBox [0 0 595.2799999999999727 841.8899999999999864]
/Contents 12 0 R
>>
endobj
12 0 obj
<<
/Length 3233
>>
stream
0.5670000000000001 w
0.78 G
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 756.8506299212598378 Td
(45. [Patient Experience] Does the center have systems for measuring customer satisfaction? \(patient,) Tj
T* (sponsor\)) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 722.8348818897637784 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 694.4884251968503577 Td
(46. [Patient Experience] Is there a formal transfer management system that guarantees that the) Tj
T* (patient does not incur any economic expense?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 660.4726771653542983 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 632.1262204724408775 Td
(47. [Start Up] What is the average total time from the first submission of documentation to final) Tj
T* (approval by the IEC/IRB? Do you use a local, central, or both IEC? Does your IEC have any extra) Tj
T* (requirements for the submission/approval of documents?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 583.9372440944881646 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 555.5907874015747439 Td
(48. [Start Up] Does the site have the capacity to submit documentation to its Ethics Committee) Tj
T* (\(IEC/IRB\) prior to the signature/execution of the contract?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 521.5750393700786844 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 493.2285826771653205 Td
(49. [Start Up] Does the composition of the IEC/IRB members comply with ICH-GCP requirements?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 473.3860629921259147 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 445.0396062992125508 Td
(50. [Start Up] Is there a clearly defined person responsible for start-up management?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 425.1970866141731449 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 396.850629921259781 Td
(51. [Start Up] How is the comprehensive review of the protocol performed before the start) Tj
T* (\(operational feasibility, vendors, required resources\)?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 362.8348818897637216 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 334.4884251968503008 Td
(52. [Recruitment] What methods has the site used for recruiting patients for clinical research? Is the) Tj
T* (site willing to carry out active dissemination and promotion actions of the study towards other local) Tj
T* (sites and/or referral networks?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 286.2994488188975311 Td
(Answer: Not Answered) Tj
ET
BT
/F2 10 Tf
11.5 TL
0.235 g
56.6929133858267775 257.952992125984224 Td
(53. [Post Study] Is the management of physical and digital archives post-study closure clearly) Tj
T* (defined? Is there a follow-up of SAEs once the study is concluded?) Tj
ET
BT
/F1 10 Tf
11.5 TL
0. g
70.8661417322834666 223.9372440944881646 Td
(Answer: Not Answered) Tj
ET
BT
/F1 8 Tf
9.1999999999999993 TL
0.588 g
230.4777952755905801 28.3464566929134207 Td
(Generated on 9/2/2026 - Innova Trials) Tj
ET
endstream
endobj
1 0 obj
<</Type /Pages
/Kids [3 0 R 5 0 R 7 0 R 9 0 R 11 0 R ]
/Count 5
>>
endobj
13 0 obj
<<
/Type /Font
/BaseFont /Helvetica
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
14 0 obj
<<
/Type /Font
/BaseFont /Helvetica-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
15 0 obj
<<
/Type /Font
/BaseFont /Helvetica-Oblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
16 0 obj
<<
/Type /Font
/BaseFont /Helvetica-BoldOblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
17 0 obj
<<
/Type /Font
/BaseFont /Courier
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
18 0 obj
<<
/Type /Font
/BaseFont /Courier-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
19 0 obj
<<
/Type /Font
/BaseFont /Courier-Oblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
20 0 obj
<<
/Type /Font
/BaseFont /Courier-BoldOblique
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
21 0 obj
<<
/Type /Font
/BaseFont /Times-Roman
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
22 0 obj
<<
/Type /Font
/BaseFont /Times-Bold
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
23 0 obj
<<
/Type /Font
/BaseFont /Times-Italic
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
24 0 obj
<<
/Type /Font
/BaseFont /Times-BoldItalic
/Subtype /Type1
/Encoding /WinAnsiEncoding
/FirstChar 32
/LastChar 255
>>
endobj
25 0 obj
<<
/Type /Font
/BaseFont /ZapfDingbats
/Subtype /Type1
/FirstChar 32
/LastChar 255
>>
endobj
26 0 obj
<<
/Type /Font
/BaseFont /Symbol
/Subtype /Type1
/FirstChar 32
/LastChar 255
>>
endobj
2 0 obj
<<
/ProcSet [/PDF /Text /ImageB /ImageC /ImageI]
/Font <<
/F1 13 0 R
/F2 14 0 R
/F3 15 0 R
/F4 16 0 R
/F5 17 0 R
/F6 18 0 R
/F7 19 0 R
/F8 20 0 R
/F9 21 0 R
/F10 22 0 R
/F11 23 0 R
/F12 24 0 R
/F13 25 0 R
/F14 26 0 R
>>
/XObject <<
>>
>>
endobj
27 0 obj
<<
/Producer (jsPDF 4.1.0)
/CreationDate (D:20260209235359-03'00')
>>
endobj
28 0 obj
<<
/Type /Catalog
/Pages 1 0 R
/OpenAction [3 0 R /FitH null]
/PageLayout /OneColumn
>>
endobj
xref
0 29
0000000000 65535 f 
0000019233 00000 n 
0000021080 00000 n 
0000000015 00000 n 
0000000152 00000 n 
0000003746 00000 n 
0000003883 00000 n 
0000007757 00000 n 
0000007894 00000 n 
0000011782 00000 n 
0000011920 00000 n 
0000015808 00000 n 
0000015947 00000 n 
0000019315 00000 n 
0000019441 00000 n 
0000019572 00000 n 
0000019706 00000 n 
0000019844 00000 n 
0000019968 00000 n 
0000020097 00000 n 
0000020229 00000 n 
0000020365 00000 n 
0000020493 00000 n 
0000020620 00000 n 
0000020749 00000 n 
0000020882 00000 n 
0000020984 00000 n 
0000021333 00000 n 
0000021419 00000 n 
trailer
<<
/Size 29
/Root 28 0 R
/Info 27 0 R
/ID [ <6740154BFE5AD3E4311A92109CA8E5F4> <6740154BFE5AD3E4311A92109CA8E5F4> ]
>>
startxref
21523
%%EOF